 .			· · · · · · · · · · · · · · · · · · ·	Sheet 1 of 18
]	Form	PTO-1449 Modified	Docket No.	Serial No.
			5.US10.CON	Not Assigned
	(FPatent and Publications Cited by Applicant everal sheets if necessary)	Applicant Dominic P. Behan,	et al.
		epartment of Commerce t and Trademark Office	Filing Date Herewith	Group Not Yet Assigned
(OTHE	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)
nlm	AA Gdaniec, M., et al. "Crystal and molecular structure of 3-(4-chlor=benzoylimino			
	AB	Gdaniec, M., et al., "Crystal and molecular structure of 3-(4-chlorobenzoylimino)-5, dih ydro-3H-imidazo[2,1-c]-1,2,4-dithiazole," Chemical Abstracts XP-002177676, 1989, 19(3), 1 page		
	AC	Saczewaki, F., "Synthesis, transform aroylthiocarbamoyl)imidazolidine-2-1993, 121(7), 1 page	ations and tuberculosta thiones," Chemical Ab	atic activity of 1-(N-stracts XP-002177673,
	AD Saczewski, F., "Synthesis transformations and tuberculostatic activity oflaroylthiocarbamoyl)imidazolidine-2-thiones," Chemical Abstracts XP-002177675, 1993, 1 page			
	AE	E Saczewski, F., et al., "Synthesis and transformations of 3-benzoylimino-5,6-dihydro-3H-imidazo[2,1-c][1,2,4]dithiazole," Communications, September 1986, 751-753		
1	AF	PCT International Search Report dated October 9, 2001		
	<u> </u>			
EXAMINE	R	K) , M. F. Bn	DATE CONSIDER	ED 3/10/0

the referrer croned out were not frontel.

Sheet 2 of 18

Form PTO-1449 Modified	Docket No. / 5.0S10.	· · · · · · · · · · · · · · · · · · ·	J	
	/5.US10.	CON Not Ass	5	
		CON INCL MES.	igned	
List of Patent and Publications	Applicant			
Cited by Applicant		Dominic P. Behan, et al.		
(Use several sheets if necessary)	Donamic 1	. Delian, et al.		
•				
U.S. Department of Commerce	Filing Dat			
Patent and Trademark Office	. Herewit	h. Not Yet	Assigned	
U. S. PA	TENT DOCUMENTS	5		
Examiner Document				
Initial No. Dat	e Name	Class	Subclass	
			1	
·				
		·		
			 	
FOREIGN	PATENT DOCUME	NTS		
Examiner		Tr	anslation	
Initial Document No. Date	e Country	YES	NO	
NW AG WO 99/09024 02/	25/99 PCT			
			×	
			 	
EXAMINER WWW.	DATE C	onsidered 3/	30/00	

		Sheet ³ of ¹⁸
1449 Modified	Docket No.	Serial No.
	5ÚS10.CON	Not Assigned
Applicant	Applicant Dominic P. Behan et al.	
	Filing Date Herewith	Group Not Yet Assigned
CUMENTS (Including Autho	or, Title, Date, Perti	nent Pages, Etc.)
	•	
Seifert, R. et al., "Different effects of Gs alpha splice variants on beta-2-adrenoreceptor-mediated signaling, J. Biol. Chem., 1998, 273, 5109-5116.		
Wise, A. et al., "Rescue of functional interactions between the alpha-2A-adrenoreceptor and acylation-resistant forms of Gil-alpha aby expressing the proteins from chimeric open reading frames," J. Biol. Chem., 1997, 272, 24673-24678.		
Burt, A.R., et al., "Agonist occupation of an alpha-2A-adrenoreceptor-Gil-alpha fusion protein results in activation of both receptor-linked and endogenous Gi proteins". J. Biol. Chem., 1997, 283, 10367-10375.		
<u> </u>	·	
····		
nd Sh	DATE CONSIDI	ERED 3/11/0
	A. et al., "Cellular signaling on", Proc. Natl. Acad. Sci. USA or ceceptor-mediated signaling. A. et al., "Rescue of functions or ceceptor and acylation-resistate chimeric open reading frames, A.R., et al., "Agonist occupation protein results in activation of	and Publications Applicant neets if necessary) ent of Commerce rademark Office CUMENTS (Including Author, Title, Date, Perticular signaling by an agonist-activate, Proc. Natl. Acad. Sci. USA, 1994, 91, 8827-88 et, R. et al., "Different effects of Gs alpha splice var preceptor-mediated signaling, J. Biol. Chem., 1998, A. et al., "Rescue of functional internations between the proceptor and acylation-resistant forms of Gil-alpha chimeric open reading frames," J. Biol. Chem., 1998, A.R., et al., "Agonist occupation of an alpha-2A-activation of both receptor-linkens". J. Biol. Chem., 1997, 283, 10367-10375.

				- <u>. </u>		Sheet 4 of 18	
F	List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office			Docket No.			
1				Filing Date Herewith	Group Not Ye	et Assigned	
		U. S	. PATENT D	OCUMENTS			
Examiner Initial	-	Document No.	Date	Name	Class	Subclass	
					·		
	,	FORE	IGN PATENT	T DOCUMENTS			
Examiner Initial		Document No.	Date	Country	YES	anslation NO	
hw	BE	WO 98/46995	22.10.98	PCT .	×		
-7							
						-	
EXAMINE	R	Jack		DATE CONSIDE	ERED	3/30/07	

· ...

			 			Sheet of 10
I	form l	PTO-1449 Modifi	ed	Docket No.	Serial No	
				5.US10.CON	Not A	ssigned
	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Behan et al.		
	U.S. Department of Commerce Patent and Trademark Office			Filing Date Herewith	Group	Yet Assigned
		U. S	. PATENT DO	OCUMENTS		
Examiner Initial		Document No.	Date	Name	Class	Subclass
						•
					-	
	ļ <u>.</u>					
				i		
· 						·
-						
						
		FORE	IGN PATENT	DOCUMENTS		<u> </u>
Examiner Initial		Document No.	Date	Country	YES	ranslation NO
PV	éea	2,135,253	08.05.96	Canada	X	
	<u> </u>					
	<u> </u>					
EXAMINE	R	Wina sh	-	DATE CONSID	ered 3	130157

Form	PTO-1449 Modified	Docket No. 5. US10 CON	Serial No. Not::Assigned		
	of Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Dominic P. Behan	et al.		
i e	Department of Commerce nt and Trademark Office	Filing Date Herewith	Group Not Yet Assigned		
ОТН	ER DOCUMENTS (Including Autho	or, Title, Date, Pertin	ent Pages, Etc.)		
NIB DA	Alla, S.A. et al., "Extracellular domaligand binding and agonist sensing of 1996, 271, 1748-1755	•	•		
·DB	Advenier, C. et al., "Effects on the is and selective nonpeptide antagonist Respir. Dis., 1992, 146(5, Pt. 1), 11	of the neurokinin A			
DC		Alexander, W.S. et al., "Point mutations within the dimer interfact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , 1995, 14(22), 5569-5578			
DD		Arvanitikis, L. et al., "Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation," <i>Nature</i> , 1997, 385, 347-349			
DE	Barker, E.L. et al., "Constitutively a novel inverse agonist activity of rec 11687-11690				
DF	Baxter, G., "5-HT ₂ receptors: a familio5-110	Baxter, G., "5-HT ₂ receptors: a family re-united?" Trends Pharmacol. Sci., 1995, 16, 105-110			
DG	1	Besmer, P. et al., "A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family," Nature, 1986, 320, 415-421			
OH.	Blin, N. et al., "Mapping of single amino acid residues required for selective activation of $G_{\phi/11}$ by the m3 muscarinic acetylcholine receptor," J. Biol. Chem., 1995, 270, 17741-17748				
. AI DI	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in Receptor-Based Drug Design, Leff, P. (ed.), New York, M. Dekker, 1998, 363-377				
ή pi	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype," Proc. Natl. Acad. Sci. USA, 1993, 90(21), 9921-9925				
EXAMINER 1	sew	DATE CONSIDE	RED 3/360		

				,	Sheet 7 of 18	
•	•	Form	PTO-1449 Modified	Docket No.	Serial No.	
				5".US10.CON	Not Assigned	
			Patent and Publications	Applicant		
			Cited by Applicant	Dominic P. Behan	et al.	
		(Use se	veral sheets if necessary)			
	U.S. Department of Commerce Filing Date Group					
<u>.</u>			t and Trademark Office	Herewith:	Not Yet Assigned	
		OTHE	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	ent Pages, Etc.	
M	ß	DK	Burstein, E.S. et al., "Constitutive ac and delineation of G-protein coupling 1996, 51(4), 539-544		- 1	
		DL	Burstein, E.S. et al., "Amino acid sid protein coupling. Studies of the third 2882-2885		-	
		DM	Burstein, E.S. et al., "Constitutive ac G _q ," FEBS Lett., 1995, 363(3), 261-2		receptors by the G-protein	
		DN	Bylund, D., "International union of p Pharmacol. Rev., 1994, 46, 121-136	,	lature of adrenoceptors,"	
		DO		Casey, C. et al., "Constitutively active mutant 5-HT _{2A} serotonin receptors: inverse agonist activity of classical 5HT _{2A} antagonists," Soc. Neurosci., 1996, Abstract #699.10		
		DP	Cheatham, B. et al., "Substitution of activates the insulin receptor and mo Proc. Natl. Acad. Sci. USA, 1993, 90	dulates the action of i		
		 DQ	Chen, J. et al., "Tethered Ligand Lib Chem., 1995, 270, 23398-23401	rary for Discovery of	Peptide Agonists," J. Biol.	
		DR	Chen, T.S. et al., "Microbial hydrox (AII) receptor antagonist MK 954,"			
		DS	Chen, W. et al, "A colorimetric assay for measuring activation of G _s - and G _q -coupled signaling pathways," <i>Anal. Biochem.</i> , 1995, 226(2), 349-354			
		DT	Chidiac, P. et al., "Inverse agonist activity of β-adrenergic antagonists," J. Pharm. Exp. Thar., 1994, 45, 490-499			
Clozel, M. et al., " In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology," J. Cardiovas. Pharmacol., 1993, 22(Suppl. 8), S377-S379						
EXAM	IINI	ER	\rack	DATE CONSIDE	RED 3/36/D	
	EXAMINER $\sqrt{\frac{3}{3}6/6}$					

Sheet 8 of 18

Form	PTO-1449 Modified	Docket No.	Serial No.		
		5.US10.CON	Not Assigned		
	f Patent and Publications	Applicant	4		
	Cited by Applicant everal sheets if necessary)	Dominic P. Baff	han,		
	Department of Commerce nt and Trademark Office	Filing Date Herewith	Group Not Yet Assigned		
ОТН	ER DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)		
N/~ DV	Collesi, C. et al., "A splicing variant or kinase activity and an invasive phenoty				
DW .	Cooper, C.S. et al., "Molecular clonitransformed human cell line," Nature	_	ng gene from a chemically		
DX	De Dios, I. et al., "Effect of L-364,7" Pancreatic Secretion of Hydrocortise				
	Desbios-Mouthon, C. et al., "Deletion				
DY	receptor causes constitutive activation Clin. Endocrinol. Metab., 1996, 81(2)	-/	nsulin desensitization," J.		
DZ	Di Renzo, M.F. et al., "Expression o human tissues," Oncogene, 1991, 6(or in normal and neoplastic		
;. DAA	Di Renzo, M.F. et al., "Overexpressi thyroid carcinomas," Oncogene, 199		receptor gene in human		
DAB	Duprez, L. et al., "Germline mutations autoimmune autosomal dominant hyper		· · · · · · ·		
DAC	Eggericksx, D. et al., "Mølecular Cle that Constitutively Activates Adeny				
EA. DAE	Evans, B.E. et al., "Orally Active, N 1992, 35, 3919-3927	onpeptide Oxytocin A	ntagonists," J. Med. Chem.,		
;;;;	Fu, M. et al., Functional autoimmune epitope on α ₁ -adrenergic receptors in patients with malignant hypertension, Lancet, 1994, 344, 1660-1663				
DAG	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto- oncogene c-kit in a Human Mast Cell Leukemia Cell Line Causing Ligand- independent Activation of c-kit Product," J. Clin. Invest., 1993, 92, 1736-1744				
DAH	Gellai, M. et al., "Nonpeptide Endothelin Receptor Antagonists V: Prevention and Reversal of Acute Renal Failure in the Rat by SB 209670," J. Pharm. Exp. Therap., 1995, 275(1), 200-206				
EXAMINER	Men	DATE CONSIDER	RED 7/30/0		

Form	PTO-1449 Modified	Docket No. 5.US10.CON	Serial No.	
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Dominic P. Behan et al.		
U.S. I Pater	Group 			
ОТНЕ	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
N/B DAI	Gitter, B. et al., "Pharmacological Cl Selective Nonpeptide Substance P (N Exp. Therp., 1995, 275(2), 737-744			
DAJ	Gouilleux-Gruart, V. et al., "STAT-F Activated in Peripheral Blood Cells 1 87(5), 1692-1697			
DAK	Hansson, J.H. et al., "Hypertension of subunit: genetic heterogeneity of Lid	• /	•	
DAL	Hasegawa, H. et al., "Two Isoforms of Different in Agonist-independent Co 1857-1860	. , -	•	
DAM	Hendler, F. et al., "Human Squamous Growth Factor Receptors," J. Clin. I.	_	-	
DAN	Herrick-Davis, K. et al., "Constitutive by Site-Directed Mutagenesis," Soc.	•	-	
DAO	Hieble, J., "International union of ph nomenclature of 1-adrenoceptors," F	. ••		
;) DAP	Hill, S., "Distribution, Properties, an Histamine Receptor," Am. Soc. Phan			
∂P DAQ	Högger, P/et al., "Activating and Inactivating Mutations in – and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," J. Biol. Chem., 1995, 270(13), 7405-7410			
F DAR	Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene c-kit in Acute Myeloblastic Leukemia Cells," Blood, 1991, 78(11), 2962-2968			
Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," Mol. Pharm., 1992, 42, 982-990				
EXAMINER	I she m	DATE CONSIDER	RED 3/30/0	

Sheeto of 8

1	Form l	PTO-1449 Modified	Docket No.	Serial No. Not Assigned	
	C	Patent and Publications ited by Applicant veral sheets if necessary)	Applicant Dominic P. Behan et al.		
		epartment of Commerce and Trademark Office	Filing Date *Herewith,	Group Not Yet Assigned	
	отнен	R DOCUMENTS (Including Auth	or, Title, Date, Pertin	ent Pages, Etc.)	
15/6)}: DAT	Jakubik, J. et al., "Constitutive acti receptors in transfected CHO cells revealed by negative antagonists,"	and of muscarinic rece	eptors in the heart cells	
)	Dau	Kjelsberg, M.A. et al., "Constitutival amino acid substitutions at a single			
	DAV	Knapp, R. et al., "Molecular biolog FASEB J., 1995, 9, 516-525	gy and pharmacology o	of cloned opioid receptors,"	
	DAW	Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," <i>Human Mol. Genetics</i> , 1995, 4(2), 183-188			
	J. DAX	Kosugi, S. et al., "Identification of Interaction Sites in the N-Termina Endocrinology, 1993, 7, 114-130			
	DAY	Kraus, M. et al., "Demonstration of tyrosine kinase and its constitutive Natl. Acad. Sci. USA, 1993, 90, 29	activation in human b	naling by the erbB-3 reast tumor cells," Proc.	
		Kudlacz, E. et al., "In Vitro and In Nonpeptide NK-1/NK-2 Vachykin 1996, 277(2), 840-851	•	•	
	DBA	Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine Phosphorylation and Activation of the Proto-oncogene c-kit Product," Blood, 1991, 78(11), 2834-2840			
	DBB	Labbé-Jullié, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and tw enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," J. Pharm. Exp. Therap., 1994, 271(1), 267-276			
	Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," J. Clin. Endocrinol. Metabl., 1995, 80(8), 2490-2494				
EXAMIN	ER	Winch	DATE CONSIDER	RED 3/36/s	

Sheet 110f 18

]	Form 1	PTO-1449 Modified	Docket No. 5.US10.CON	Serial No.
	C	Patent and Publications lited by Applicant veral sheets if necessary)	Applicant Dominic P. Behan et al.	
		epartment of Commerce and Trademark Office	Filing Date Herewith	Group Not Yet Assignied
	OTHE	R DOCUMENTS (Including Autho	or, Title, Date, Perti	nent Pages, Etc.)
PER	DBD	Laue, L. et al., "Genetic heterogene human luteinizing hormone recepto Proc. Natl. Acad. Sci USA, 1995, 92	r in familial male-lin	_ /
DMS	DBE	Løvlie, R. et al., "The Ca2+-sensing isolated autosomal dominant hypop		
	DBF	Lefkowitz, R. et al., "Constitutive a regulatory proteins," Trends Pharm	/	
	DBG	rearrangement of EGF recentor gene in primary/numan brain tumours of glial		
	C: DBH	Liu, C. et al., "Overexpression of c-factor receptor or c-erbB-2 in prima 1992, 7, 181-185		
	DBI	Liu, J. et al., "Molecular mechanism mediated G protein activation studi 1996, 271(11), 6172-6178		
	C [™] . DBJ	Lonardo, F. et al., "The normal erbi kinase with constitutive activity in 2(11), 992-1003		
	© I	Maenhaut, C. et al., "RDC8 codes for constitutive activity," Biochem. Bio		
	OBL	Mann, J. et al., "Increased serotonin ₂ and β-adrenergic receptor binding in the front cortices of suicide victims," Arch. Gen. Psychiatry, 1986, 43, 954-959		
	Martone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, 1996, Abstract No. 609.8			
V	CFA DBN	Magnusson, Y. et al., "Autoimmun Circulation, 1994, 89, 2760-2767	ity in idiopathic dilat	ted cardiomyopathy,"
XAMINI	ER	Vinca	DATE CONSIDE	ERED 3/30/02

Sheetibaf 18

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone recepter carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenop Oocytes and AtT20 Cells," J. Biol. Chem., 1995, 270(3), 1041-1047 Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essenti kinase activity and macrophage colony-stimulating factor-dependent internalizating Mol. Cell. Biol., 1994, 14(7), 4843-4854 Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 19271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic necoplasms: demonstration of the relationship to malignant melanoma turnour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040 Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955				T	Sheet 12 f 18	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor activating and leads to impaired responsiveness in Xenop Occytes and Art20 Cells," J. Biol. Chem., 1995, 270(3), 1041-1047 Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essentia kinase activity and macrophage colony-stimulating factor-dependent internalizating Mol. Cell. Biol., 1994, 14(7), 4843-4854 Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 19 271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040) Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and DBM Paffitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid		Form	PTO-1449 Modified	Docket No.	Serial No.	
Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office Patent and Trademark Office OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenop Occytes and AtT20 Cells," J. Biol. Chem., 1995, 270(3), 1041-1047 Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essenti kinase activity and macrophage colony-stimulating factor-dependent internalizati Mol. Cell. Biol., 1994, 14(7), 4843-4854 Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 19 271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040) Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. Th. 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of thuman β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and Chem., 1996, 271(14), 7949-7955				5.US10.CON	Not Assigned	
U.S. Department of Commerce Patent and Trademark Office OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone recept carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenop Occytes and AtT20 Cells," J. Biol. Chem., 1995, 270(3), 1041-1047 Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essentic kinase activity and macrophage colony-stimulating factor-dependent internalization. Mol. Cell. Biol., 1994, 14(7), 4843-4854 Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 1927(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic necoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040 Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium propride (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human pla-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Ga ₁₃ and Ga ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. Biol. Chem., 1996, 271(14), 7949-7955	•	(Cited by Applicant		et al.	
Patent and Trademark Office OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenop Occytes and AtT20 Cells," J. Biol. Chem., 1995, 270(3), 1041-1047 Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essentikinase activity and macrophage colony-stimulating factor-dependent internalization Mol. Cell. Biol., 1994, 14(7), 4843-4854 Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 1922, 271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma turnour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040 Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium propride (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human pla-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Ga ₁₃ and Ga ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. Biol. Chem., 1996, 271(14), 7949-7955				Pit D	T	
Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenop Oocytes and Att720 Cells," J. Biol. Chem., 1995, 270(3), 1041-1047 Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential kinase activity and macrophage colony-stimulating factor-dependent internalization Mol. Cell. Biol., 1994, 14(7), 4843-4854 Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 19271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic necoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040 Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. Biol. Chem., 1996, 271(14), 7949-7955					Group Not Yet Assigned	
Carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenop Occytes and AtT20 Cells," J. Biol. Chem., 1995, 270(3), 1041-1047 Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essentikinase activity and macrophage colony-stimulating factor-dependent internalizating Mol. Cell. Biol., 1994, 14(7), 4843-4854 Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 19: 271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040 Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of th human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Ga ₁₅ and Ga ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955		OTHE	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	ent Pages, Etc.)	
Natali, P.G. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 19: 271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040) Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Ga ₁₅ and Ga ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid	kin		carboxyl tail causes constitutive activity	and leads to impaired r	esponsiveness in Xenopus	
DBQ 271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040 Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. Biol. Chem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid			kinase activity and macrophage color	ny-stimulating factor-o	rane domain is essential for lependent internalization,"	
DER neoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040 Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natrium peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroic		DBQ		tor activating mutation	as," J. Biol. Chem., 1996,	
a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(26037-26040) Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriure peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. Biochem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid			Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-749			
DBT peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-ind inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. The 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid		DBS	Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(44), 26037-26040			
human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroic		•	inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. Ther.,			
Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid		DBU	O'Dowd, B.F. et al., "Site-directed in human β2-adrenergic receptor," J. Bi	nutagenesis of the cyto iol. Chem., 1988, 263(plasmic domains of the 31), 15985-15992	
DBW triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroidents."			Offermanns, S. et al., "Ga ₁₅ and Ga ₁₆ Phospholipase C," J. Biol. Chem., 19	Couple a Wide Varie 195, 270, 15175-15180	ty of Receptors to	
DBX constitutively active forms of the human platelet-activating factor receptor," J. B. Chem., 1996, 271(14), 7949-7955 Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroidents."			Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of			
			Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. Biol.			
hyperparathyroidism," J. Clin. Endocr. Metabl., 1996, 81, 3584-3588	4	DBY hormone (PTH)/PTH-related peptide receptor: comparison with primary				
EXAMINER DATE CONSIDERED 3/70/0	EXAMINE	R	Vivín	DATE CONSIDER	ED 3/70/0	

]	Form]	PTO-1449 Modified	Docket No. 5.US10.CON	Serial No. Not Assigned	
	C	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Dóminic P. Behan e	t al.	
		epartment of Commerce and Trademark Office	Filing Date Herewith	Group Not Yet Assigned	
	OTHE	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
1519	DBZ	Samama, P. et al., "A mutation-inducereceptor," J. Biol. Chem., 1993, 2686		the β2-adrenergic	
	: DCA	Sautel, M. et al., "Neuropeptide Y ar overlapping binding site at the huma 1996, 50, 285-292			
	DCB	Sawutz, D.G. et al., "Pharmacology nonpeptide bradykinin receptor anta 1995, 13, 805-811			
6/6	DCC	Scheer, A. et al., "Constitutively active of receptor activation," J. Rec. Signal			
Nin	⊕o DCD	Scheer, A. et al., "The activation pro of protonation and hydrophobicity of Sci. USA, 1997, 94, 808-813			
	DCE	Schwinn, D.A. et al., "Cloning and I adrenergic receptors: sequence conhomologues," J. Pharmacol., 1995,	rrections and direct con	cterization of human Alpha- mparison with other species	
)CF	Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the <i>Xenopus laevis</i> oocyte expression system," <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 92, 5699-5703			
	DCG	Seeman, P. et al., "Dopamine receptor pharmacology," Trends Pharmacol. Sci., 1994, 15, 264-270			
	DCH	Seeman, P. et al., "Dopamine D4 re 365, 441-445	ceptors elevated in sch	izophrenia," Nature, 1993,	
	DCI	Serradeil-Le Gale, C. et al., "Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V _{1a} receptors," J. Clin. Invest., 1993, 92, 224-231			
Y	I co	Sharif, M. t al., "Malignant transfo Mol. Cell. Endocrinology, 1994, 10		coupled hormone receptors,"	
EXAMIN	ER	Mind Syr.	DATE CONSIDE	RED 3/30/07	

		Form	PTO-1449 Modified	Docket No.	Serial No.	
		(Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Dominic P. Behan e		
			epartment of Commerce t and Trademark Office	Filing Date Herewith	Group Not Yet Assigned	
		OTHE	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
105	18	: DCK	Jensen et al., "mRNA Profiling of Rat Homeodomain Transcription Factor," J.			
		DCI.	Konig et al., "Method for Identifying Receptors," Mol. Cell. Neuro., 1991,	_	Cloned G _i - or G _i -Coupled	
		DCM	Leonard, J. et al., "The LIM family to element binding protein to promote s Proc. Natl. Acad. Sci. USA, 1992, 89	omatostatin expression	-	
		DCN	Marchese, A. et al., "Cloning of Hun Receptors," Genomics, 1994, 23, 609	,	ovel G Protein-Coupled	
). DCO	Marks, D.L. et al., "Simultaneous Vi Individual Neurons by Use of a New Cell. Neuro., 1992, 3, 395-405	,	-	
		DCP	O'Dowd, B. et al., "Cloning and chro G-protein-coupled receptor genes," (
•		DCO	Sakurai T. et al., "Orexins and Orexin R Protein-Coupled Receptors that Regulate Fe			
		DCR	Song, ZH. et al., "Molecular Cloning a Three Closely Related to Protein-Coupled R			
		DCS	Suzuki, M. et al, "Regulatable Promotes the 5'-Flanking Region of the CFTR Gene value Low-Level Gene Expression that can be Up Levels of cAMP," Human Gene Therap	vith Multiple cAMP Respo regulated by Exogenous A	nse Elements to Support Basal, gents that Raise Intracellular	
		DCT	Xu, Y. et al., "Identification of Human OGR1, a Novel G Protein-Coupled Receptor That Maps to Chromosome 14," Genomics, 1996, 35, 397-402			
•		DCU	Nichols, J.G. et al. (eds.), "Indirect Neuron To Brain, 3rd Edition, Sinat			
\	Osl et al. (eds.), in Remington's Pharmaceutical Sciences, 16th Edition, Mack Publishing Co., 1980					
EXAM	<u>(IN</u>	ER	Val Ca	DATE CONSIDER	RED 3/20/80	

A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

Sheet 5nf 18

]	Form	PTO-1449 Modified	Docket No. 5.US107CON	Serial No. Not Assigned	
٠.	(Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Dominic P. Behan e	t al.	
		epartment of Commerce t and Trademark Office	Filing Date Herewith	Group Not Yet Assigned	
	ОТНЕ	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
NIB	DCW	Parma, J. et al., "Somatic mutations in hyperfunctioning thyroid adenomas,"		_	
	DCX	Pei, G. et al., "A constitutive active a desensitized and phosphorylated," P			
	DCY	Pendley, C.E. et al., "The gastrin/chol basal acid secretion and prevents gastro cysteamine in the rat," J. Pharmacol.	intestinal damage induc	ed by aspirin, ethanol and	
	DCZ	Peroutka, S., "Serotonin receptor sul CNS Drugs, 1995, 4 (Suppl. 1), 18-2		n and clinical relevance,"	
	DDA	Pettibone, D.J. et al., "Development and nonpeptide oxytocin antagonists			
	ĎDВ	Prat, M.P. et al., "The receptor encohepatocytes, epithelial cells and soli	•	= · =	
	DDC	Prezeua, L. et al., "Changes in the ca glutamate receptor 1 by alternate spi independent activity," Mol. Pharma	licing generate recepto	rs with differing agonist-	
	DDD	Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced contractions and ³ H-acetylcholine release from guinea-pig gallbaldder," <i>Neuropeptides</i> , 1993, 25(5), 271-276			
·	DDE	Ren, Q. et al., "Constitutive active no Chem., 1993, 268, 16483-16487	nutants of the α_2 -adren	ergic receptor," J. Biol.	
	: DDF	Reynolds, E.E. et al., "Pharmacolog active ET _A receptor antagonist," J. I		· · · · · · · · · · · · · · · · · · ·	
	ारू DDG	Robbins, L.S. et al., "Pigmentation from point mutations that alter MSI			
	DDH	Rong, S. et al., "Met expression and 5355-5360	l sarcoma tumorigenici	ity," Cancer, 1993, 53(22),	
EXAMINI	ER	V. M.	DATE CONSIDE	RED 3/30/07	

	Form	PTO-1449 Modified	Docket No.	Serial No. Not Assigned
	(Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Dominic P. Behan e	t al.
		epartment of Commerce t and Trademark Office	Filing Date Herewith	Group Not Yet Assigned
	ОТНЕ	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)
.1011	DDI	Showers, M.O. et al., "Activation of focus-forming virus gp55 glycoprote phosphorylation," <i>Blood</i> , 1992, 80(1)	in induces constitutive	
	ŢDDJ	Skinner, R.H. et al., "Direct measure using scintillation proximity assay,"		
	DDK	Slamon, D.J. et al., "Human breast ca amplification of the HER-2/neu onco		
	DDL E	Slamon, D. et al., "Studies of the HE ovarian cancer," Science, 1989, 244,		ne in human breast and
	DDM	Salomon, Y. et al., "A highly sensitive 1974, 58, 541-548	ve adenylate cyclase as	ssay," Anal. Biochem.,
	DDN	Spiegel, A.M., "Defects in G protein Ann. Rev. Physiol., 1995, 58, 143-17	•	uction in human disease,"
	DDO	ter Laak, A. et al., "Modelling and mu binding site reveal different binding mo role in receptor stimulation," J. Compu	odes for H ₁ -agonists: Asp	o ¹¹⁶ (TM3) has a constitutive
	DDP	Tiberi, M. et al., "High agonist-inder dopamine D1B receptor subtype," J.		
	 DDQ	Tsujimura, T. et al., "Constitutive accells caused by deletion of seven am 1996, 87(1), 273-283		
	DDR	Wang, Z. et al., "Constitutive μ opic underlying narcotic tolerance and de		
N	出席 DDS	Watowich, S.S. et al., "Homodimeri erythropoietin receptor," <i>Proc. Natl.</i>		
EXAMIN	ER	Vin Ch	DATE CONSIDER	VED 3/30/07

	Form	PTO-1449 Modified	Docket No. 5.US10.CON	Serial No.	
	(Patent and Publications Cited by Applicant Everal sheets if necessary)	Applicant Dominic P. Behan e		
		epartment of Commerce t and Trademark Office	Filing Date Herewith Not Yet Assigned		
	OTHE	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
NIB	DDT		tive activation of STAT proteins in primary ls and in Epstein-Barr virus (EBV)-related 88(3), 809-816		
	DDU	Webster, M.K. et al., "Constitutive act transmembrane point mutation found in		•	
	DDV	Xu, Y. et al., "Characterization of epidem and normal human cell lines," Proc. Natl.	_		
	DDW				
·	DDX	Zhang, S. et al., "Identification of Dynorphins as Endogenous Ligands for an Op Receptor-Like Orphan Receptor," J. Biol. Chem., 1995, 270, 22772-22776			
	Zhen, Z. et al., "Structural and functional domains critical for constitutive a of the HGF-receptor (Met)," Oncogene, 1994, 9, 1691-1697 Gantz, I. et al., "Molecular Cloning of a Novel Melanocortin Receptor," J. Chem., 1993, 268(11), 8246-8250				
				in Receptor," J. Biol.	
	DEA	Heiber, M. et al., "Isolation of Three Novel Human Genes Encoding G Protein-Coupled Receptors," DNA and Cell Biology, 1995, 14(1), 25-35			
	DEB	Howard, A.D. et al., "A Receptor in Growth Hormone Release," Science,		lamus That Functions in	
	DEC	Protein-Coupled Receptor (GPR3) E	Iismaa, T.P. et al., "Isolation and Chromosomal Localizations of a Novel Human G-Protein-Coupled Receptor (GPR3) Expressed Predominantly in the Central Nervous System," Genomics, 1994, 24, 391-394		
1	ZQ DED	Itoh, H. et al., "Molecular cloning ar subunits of the guanine nucleotide-b Proc. Natl. Acad. Sci. USA, 1986, 83	inding proteins G, G,		
EXAMIN	ER	Nm Cm	DATE CONSIDER	ED 3/30/8)	

						Sheet 18 of 18	
F	orm]	PTO-1449 Modi	Docket No. 5US.10.CON				
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Applicant Dominic P. Behar	Applicant Dominic P. Behan et al. Filing Date Herewith Nota Yet Assigned		
U.S. Department of Commerce Patent and Trademark Office			Filing Date Herewith				
		U.	S. PATENT D	OCUMENTS			
Examiner Initial		Document No.	Date	Name	Class	Subclass	
pir	EA	5,514,578	05/07/96	Hogness et al.	435	240.2	
	ΕB	5,532,157	07/02/96	Fink	435	240.2	
	EC	5,573,944	11/12/96	Kirschner et al.	435	252.3	
	ED.	5,639,616	06/17/97	Liao et al.	435	7.1	
<u> </u>	RT EE	5,750,353	05/12/98	Kopin et al.	435	7.21	
,							
		FORI	EIGN PATEN	r documents			
Examiner Initial		Document No.	Date	Country	Translation YES NO		
	FA	WO 97/11159	09/20/96	PCT	X		
EXAMINE	R	V- / ~		DATE CONSIDE	ERED 8	Isola	